The drug candidate ABBV-0805 is a monoclonal antibody that selectively binds and eliminates oligomers and protofibrils of alpha-synuclein. The goal is to develop a disease modifying treatment that stops or slows down disease progression.
In the Parkinson’s disease treatment area, BioArctic has been collaborating with AbbVie since 2016 when a research agreement was entered into. AbbVie was granted the option to license the right to develop and commercialize BioArctic’s portfolio of antibodies against alpha-synuclein for Parkinson’s disease and other potential indications.
At the end of 2018, AbbVie exercised this option. AbbVie’s option to license the portfolio was effective after clearance by the U.S. Antitrust legislation at the end of 2018. In February 2019, the U.S. Food and Drug Administration, FDA, approved the application to conduct a clinical study with ABBV-0805 and the Phase 1 study started in March 2019. AbbVie finances and progresses the clinical development of ABBV-0805, previously called BAN0805.
The scope of the drug candidate ABBV-0805 may be expanded to include, for example, Lewy body dementia and multiple system atrophy.
The project is based on research from Uppsala University in Sweden.